Paul Bisaro

“The outstanding legal education I received at CUA combined with my experiences with the faculty and my fellow students, provided me with the basis of knowledge and confidence to deal with the complex legal, regulatory and leadership challenges I faced throughout my career. My time at CUA was, without a doubt, the single most important academic experience of my life.”

Since graduating from Law School, Mr. Bisaro has spent 30 years in various legal and executive leadership positions in the pharmaceutical sector. He has an exceptional track record of driving company growth through operational excellence, supporting innovative research and development and creative corporate transformations.

His corporate leadership experience includes serving as Chief Executive Officer of Impax Laboratories from March 2017 until May of 2018. In May of 2018, he helped lead the merger of Impax and Amneal Pharmaceuticals. Following the merger, he assumed the role of Executive Chairman of Amneal.

Prior to joining Impax, Paul served as Executive Chairman of Allergan, plc from 2014 until 2017. From 2007 until 2014, he was Chief Executive Officer of Actavis, plc (and its predecessor firm Watson Pharmaceuticals, Inc.). He also was President, Chief Operating Officer of Barr Pharmaceuticals, from 1999 to 2007. Between 1992 and 1999, Mr. Bisaro served as Barr’s General Counsel.

In addition to having served on the Board of Directors of Allergan, Actavis, Impax and Amneal, Mr. Bisaro also serves on the Board of Directors of Zoetis, Inc., a leading Animal Health Care company, and served on the Board of Zimmer Biomet Holdings, Inc., a global leader in musculoskeletal healthcare.

Lastly, prior to moving into the Corporate sector, he was associated with the law firm of Winston and Strawn and its predecessor firm, Bishop, Cook, Purcell and Reynolds from 1989 until 1992.

Mr. Bisaro has served on the Columbus School of Law’s Board of Visitors since 2013.